Treatment of myasthenia gravis.
D000085:Acetates / Q000627:therapeutic use; D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D000324:Adrenocorticotropic Hormone / Q000008:administration & dosage / Q000627:therapeutic use; D000549:Ambenonium Chloride / Q000627:therapeutic use; D000628:Aminophylline / Q000627:therapeutic use; D000779:Anesthetics, Local / Q000627:therapeutic use; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D001285:Atropine / Q000627:therapeutic use; D001965:Bromides; D002794:Choline / Q000627:therapeutic use; D002800:Cholinesterase Inhibitors / Q000008:administration & dosage / Q000494:pharmacology / Q000627:therapeutic use; D004491:Edrophonium / Q000627:therapeutic use; D006782:Hospitals, Special; D006801:Humans; D009157:Myasthenia Gravis / Q000188:drug therapy* / Q000503:physiopathology / Q000628:therapy; D009388:Neostigmine / Q000627:therapeutic use; D010830:Physostigmine / Q000627:therapeutic use; D008517:Phytotherapy; D010946:Plants, Medicinal; D010947:Plants, Toxic; D009435:Synaptic Transmission / Q000187:drug effects; D014481:United States; D014703:Veratrum / Q000627:therapeutic use
D000085:Acetates; D000305:Adrenal Cortex Hormones; D000779:Anesthetics, Local; D000889:Anti-Arrhythmia Agents; D000900:Anti-Bacterial Agents; D001965:Bromides; D002800:Cholinesterase Inhibitors; D000628:Aminophylline; D009388:Neostigmine; D000549:Ambenonium Chloride; D004491:Edrophonium; D001285:Atropine; D000324:Adrenocorticotropic Hormone; D010830:Physostigmine; D002794:Choline